moneyheap
NTLA · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Intellia Therapeutics, Inc. (NTLA) stock moving?
Intellia's Q3 2026 report on Nov 5 was a clear miss: EPS of $(0.91) against a $(0.80) estimate, and sales of $7.16M against $10.46M expected. The stock fell from $12.26 to $11.10 that day on about 7.6M shares, roughly double its typical volume. It has since traded between $11.17 and $12.11 and closed at $11.17 on Nov 10, near the lower part of its 30-day range of $10.58 to $13.94. The positives are regulatory and financial: the FDA accepted the lonvo-z BLA with Priority Review and a March 10, 2027 PDUFA date, no advisory committee is planned, cash is $614.8M with runway into 2028, and MAGNITUDE-2 enrollment is complete. Near-term newsflow is mostly conference and data presentations. J.P. Morgan keeps a Sell rating with a $9 target, below the current price. Overall the evidence is balanced: the miss is already reflected in the price, while the main upside depends on the PDUFA decision, which is still months away.
News behind the analysis
- Intellia Therapeutics to Present at Jefferies Global Healthcare ConferenceIntellia will take part in the Jefferies Global Healthcare Conference in London. No new data or guidance was disclosed in the announcement.
- J.P. Morgan Adjusts Price Target for Intellia TherapeuticsJ.P. Morgan kept a Sell rating on NTLA and raised its price target from $8 to $9. The target sits below the last close of $11.17.
- Intellia Therapeutics Announces Inducement Grants for New EmployeesIntellia granted equity-based inducement grants to three new employees as an inducement to employment. This is routine hiring activity.
- Intellia Therapeutics Q3 EPS $(0.91) Misses $(0.80) Estimate, Sales $7.163M Miss $10.461M EstimateQ3 EPS of $(0.91) missed the $(0.80) estimate, and sales of $7.163M fell well short of the $10.461M estimate. Collaboration revenue was $7.16M versus $13.78M a year earlier.
- Intellia Therapeutics Announces Third Quarter 2026 Financial ResultsIntellia reported Q3 2026 results and said it is on track to finish lonvo-z commercial readiness before the March 10, 2027 PDUFA date. Cash is expected to fund operations at least into 2028.
- Intellia Completed Enrollment In MAGNITUDE-2 Phase 3 Trial Of Nex-z In ATTRv-PN; Cash $614.8M, Expects Runway At Least Into 2028Enrollment in the MAGNITUDE-2 Phase 3 trial of nex-z is complete. Cash stood at $614.8M, with runway expected into 2028.
- Intellia Says On Track To Complete Lonvo-z Commercial Readiness Ahead Of March 10, 2027 PDUFA Date; Planned Launch In Q1 2027Intellia is on track to finish commercial readiness for lonvo-z ahead of the March 10, 2027 PDUFA date. A Q1 2027 launch is planned if approved.
- Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 TrialIntellia has completed patient enrollment for its Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z). This is a late-stage clinical milestone.
- Intellia Therapeutics Announces Upcoming Clinical Data Presentations for Nexiguran ZiclumeranIntellia will present new nex-z clinical data at the American Heart Association Scientific Sessions and the International Society of Amyloidosis Symposium in November 2026.
- Intellia Therapeutics Announces Upcoming Investor Event and ACAAI PresentationsIntellia will host an investor event and present seven abstracts at the ACAAI 2026 Annual Scientific Meeting. These events give investors more lonvo-z data in the coming weeks.
About Intellia Therapeutics, Inc
Intellia Therapeutics is a Cambridge, Massachusetts biotech developing CRISPR gene-editing therapies that are given as a one-time infusion and edit genes inside the patient's body (in vivo). Its lead drug, lonvo-z for hereditary angioedema, hit its goals in a Phase 3 trial and has an FDA decision date of March 10, 2027. If approved, it could be one of the first in vivo CRISPR treatments on the market.
How it makes money
Intellia has no approved products yet, so it doesn't sell anything. Its only revenue is small collaboration payments from partners, mainly Regeneron, of roughly $7 million a quarter in 2026. It loses about $100 million a quarter and pays for its work with cash reserves, stock sales and a loan facility of up to about $400 million. The company says its cash should last into 2028.
What usually moves NTLA
- FDA decision on lonvo-z (expected March 2027)
- Phase 3 progress and safety news for nex-z in ATTR amyloidosis
- Cash burn, share sales and dilution
- Investor views on gene-editing safety and regulation
- Biotech sector sentiment and interest rates